Lymphoma & CLL Subtypes

FDA clears investigational new drug application for ADI-001

FDA clears IND application for the first-in-class allogeneic CAR gamma-delta T-cell therapy, ADI-001.

Kieron Dunleavy invites you to join the virtual Lymphoma Hub Satellite Symposium on Nov 8, 2020

Interview with Kieron Dunleavy inviting you to the Lymphoma Hub virtual Satellite Symposium which will...

LyMa-101 trial update: Obinutuzumab for the treatment of mantle cell lymphoma

Summary of the updated results from the phase II LyMA-101 trial evaluating obinutuzumab plus high-dose cytarabine for the...

KTE-X19 receives CHMP positive opinion for the treatment of patients with R/R MCL

On October 16, 2020, brexucabtagene autoleucel received positive opinion from the EMA CHMP for the treatment of adult...

Phase I trial of the triplet therapy ipilimumab, nivolumab, and brentuximab vedotin for patients with relapsed/refractory Hodgkin lymphoma

A summary of the results from a phase I clinical trial...

Pembrolizumab receives FDA approval for extended indications in classical Hodgkin lymphoma

FDA extends indication for pembrolizumab as a monotherapy for adult and pediatric patients with cHL.

Lymphoma Hub Symposium | The value of BTK inhibitors for the treatment of patients with R/R CLL

A summary of the therapeutic value of BTK inhibitors in the R/R CLL setting and their journey into...

ASCEND final results: Acalabrutinib compared with idelalisib + R or Bendamustine + R in R/R CLL

Summary of the 6-month follow up of the phase III ASCEND trial as presented at SOHO 2020.